Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CIIT Tianci International	$0.99 +6.5%	$0.00	$0.56 ▼ $4.99	$13.75M	N/A	73,911 shs	45,080 shs
CYTR LadRx		$0.09	$0.05 ▼ $0.86	$4.14M	N/A	99,706 shs	4,000 shs
FLN First Trust Latin America AlphaDEX Fund	$20.33 +2.5%	$19.56	$15.03 ▼ $21.39	$16.26M	1.09	8,192 shs	2,370 shs
FTXH First Trust Nasdaq Pharmaceuticals ETF	$28.02 +0.8%	$26.42	$23.28 ▼ $29.72	$15.41M	0.7	7,411 shs	638 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CIIT Tianci International	+6.45%	+9.84%	-10.00%	+98,999,900.00%	+98,999,900.00%
CYTR LadRx	0.00%	0.00%	0.00%	0.00%	0.00%
FLN First Trust Latin America AlphaDEX Fund	+2.47%	+1.65%	+5.34%	+4.58%	+7.57%
FTXH First Trust Nasdaq Pharmaceuticals ETF	+0.84%	+1.91%	+3.54%	+11.41%	-4.37%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CIIT Tianci International	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CYTR LadRx	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FLN First Trust Latin America AlphaDEX Fund	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FTXH First Trust Nasdaq Pharmaceuticals ETF	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CIIT Tianci International	0.00	N/A	N/A	N/A
CYTR LadRx	0.00	N/A	N/A	N/A
FLN First Trust Latin America AlphaDEX Fund	0.00	N/A	N/A	N/A
FTXH First Trust Nasdaq Pharmaceuticals ETF	2.51	Moderate Buy	$28.02	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CIIT Tianci International	$8.62M	1.70	N/A	N/A	N/A	∞
CYTR LadRx	N/A	N/A	N/A	N/A	N/A	N/A
FLN First Trust Latin America AlphaDEX Fund	N/A	N/A	N/A	N/A	N/A	N/A
FTXH First Trust Nasdaq Pharmaceuticals ETF	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CIIT Tianci International	N/A	-$0.07	N/A	∞	N/A	-11.78%	-67.72%	-62.73%	N/A
CYTR LadRx	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
FLN First Trust Latin America AlphaDEX Fund	N/A	N/A	9.93	∞	N/A	N/A	N/A	N/A	N/A
FTXH First Trust Nasdaq Pharmaceuticals ETF	N/A	N/A	14.51	∞	N/A	N/A	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CIIT Tianci International	N/A	N/A	N/A	N/A	N/A
CYTR LadRx	N/A	N/A	N/A	N/A	N/A
FLN First Trust Latin America AlphaDEX Fund	$0.75	3.69%	N/A	N/A	N/A
FTXH First Trust Nasdaq Pharmaceuticals ETF	$0.44	1.57%	N/A	N/A	N/A

Latest CYTR, FLN, FTXH, and CIIT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/25/2025	FLN First Trust Latin America AlphaDEX Fund	Quarterly	$0.2709	5.55%	6/26/2025	6/26/2025	6/30/2025
6/25/2025	FTXH First Trust Nasdaq Pharmaceuticals ETF	Quarterly	$0.0892	1.39%	6/26/2025	6/26/2025	6/30/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CIIT Tianci International	N/A	325.42	325.42
CYTR LadRx	N/A	N/A	N/A
FLN First Trust Latin America AlphaDEX Fund	N/A	N/A	N/A
FTXH First Trust Nasdaq Pharmaceuticals ETF	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CIIT Tianci International	N/A
CYTR LadRx	N/A
FLN First Trust Latin America AlphaDEX Fund	N/A
FTXH First Trust Nasdaq Pharmaceuticals ETF	N/A

Insider Ownership

Company	Insider Ownership
CIIT Tianci International	N/A
CYTR LadRx	N/A
FLN First Trust Latin America AlphaDEX Fund	N/A
FTXH First Trust Nasdaq Pharmaceuticals ETF	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CIIT Tianci International	N/A	14.78 million	N/A	N/A
CYTR LadRx	N/A	45.04 million	N/A	Not Optionable
FLN First Trust Latin America AlphaDEX Fund	147,000	800,000	N/A	Not Optionable
FTXH First Trust Nasdaq Pharmaceuticals ETF	147,000	550,000	N/A	Optionable

CYTR, FLN, FTXH, and CIIT Headlines

Recent News About These Companies

A Look at Pharma ETFs After Strong Q1 Earnings

May 8, 2025 | zacks.com

First Trust Nasdaq BuyWrite Income ETF declares $0.207 dividend

January 22, 2025 | msn.com

Pharma ETFs in Focus Post Solid Q2 Earnings

August 14, 2024 | zacks.com

A Look at Pharma ETFs Post Q1 Earnings

May 7, 2024 | zacks.com

JNJ Beats Q1 Earnings Estimates, Misses on Sales: ETFs in Focus

April 17, 2024 | zacks.com

3 Health Care ETFs You'll Want to Own When the Market Recovers

August 3, 2022 | stocknews.com

Surprising Analyst 12-Month Target For FTXH

May 25, 2022 | nasdaq.com

First Trust Nasdaq Pharmaceuticals ETF declares quarterly distribution of $0.0488

March 25, 2022 | seekingalpha.com

Solid Q4 Earnings Fail to Impress Pharma ETFs

February 22, 2022 | nasdaq.com

Wave of Solid Q3 Earnings Push Pharma ETFs Higher

November 9, 2021 | nasdaq.com

4 ETF Strategies to Follow Warren Buffett's Vision

August 19, 2021 | msn.com

Media Sentiment Over Time

CYTR, FLN, FTXH, and CIIT Company Descriptions

Tianci International NASDAQ:CIIT

$0.99 +0.06 (+6.45%)

As of 08/22/2025 03:59 PM Eastern

The Company’s primary line of business is global logistics. The Company through its subsidiary, Roshing, provides global logistics services, encompassing booking and the transportation arrangement and related logistics solutions. Roshing’s customized logistics solutions are tailored to meet the diverse needs of its customers. As a logistics shipping operator, Roshing focuses on ocean freight forwarding services, including container shipping and bulk goods shipping service. For the container shipping service, Roshing charters cargo space from shipping suppliers (such as shipowners, ship carrier or non-vessel operating common carriers) and then sub-charters that cargo space to its customers (cargo owners or cargo agents). For the bulk goods shipping service, Roshing issues fixture notes to customers, and then arranges the booking of ships, and signs chartering contracts with suppliers (such as shipowners). Roshing also tailors the selection of transport options, and arranges to transport the goods from the port of loading to the port of destination, so as to complete the performance of the contract. Roshing currently does not own or operate any transportation assets. By leveraging our senior management’s expertise in the global logistics industry and adopting an asset-light strategy at the early stage, Roshing has seen a significant growth in logistics revenue since 2023. Shufang Gao, our Chief Executive Officer previously worked for a globally renowned shipping conglomerate, with over 20 years of management experience. His expertise spans shipping operation management, and logistics transportation. Leveraging this experience, he has provided the Company with the managerial framework to expand its global logistics business, as well as access to relevant customer and supplier resources in the shipping industry. Roshing’s business is primarily carried out in Hong Kong and other locations in the Asia-Pacific region, mainly in Japan, South Korea, Vietnam. Roshing’s logistics services also include the shipment of goods to African countries. Roshing also generates revenue from the sale of electronic parts, and certain business and technical consulting services, independent from its global logistics business. Our principal executive offices are located in Tsim Sha Tsui, Kowloon, Hong Kong.

LadRx NASDAQ:CYTR

LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded in 1985 and is headquartered in Los Angeles, CA.

First Trust Latin America AlphaDEX Fund NASDAQ:FLN

$20.33 +0.49 (+2.47%)

As of 08/22/2025 04:00 PM Eastern

The First Trust Latin America AlphaDEX Fund (FLN) is an exchange-traded fund that is based on the NASDAQ AlphaDEX Latin America index. The fund tracks an index of Latin American firms screened based on a proprietary methodology, using various factors and weighted in tiers. FLN was launched on Apr 18, 2011 and is managed by First Trust.

First Trust Nasdaq Pharmaceuticals ETF NASDAQ:FTXH

$28.02 +0.21 (+0.75%)

Closing price 08/22/2025 03:50 PM Eastern

Extended Trading

$28.02 +0.00 (+0.00%)

As of 08/22/2025 04:04 PM Eastern

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time